Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of C-CAR039 in relapsed or refractory CD19- or CD20-positive large B-cell lymphoma
CTR20222827Phase 2Active
- Sponsor
- Cellular Biomedicine Group
- Start
- Mar 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of prizloncabtagene autoleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Cellular Biomedicine Group. Started Mar 2023; status: active.
02
Drugs
prizloncabtagene autoleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20222827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222827.